These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37503262)

  • 21. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of Anti-Cancer Drugs Against Moderate and Severe COVID Infection: A Network-Based Systems Biological Approach.
    Alzahrani KJ
    Niger J Clin Pract; 2024 Aug; 27(8):950-957. PubMed ID: 39212430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.
    Ackerman EE; Shoemaker JE
    Viruses; 2020 Sep; 12(10):. PubMed ID: 32993136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 replication and drug discovery.
    Nazir F; John Kombe Kombe A; Khalid Z; Bibi S; Zhang H; Wu S; Jin T
    Mol Cell Probes; 2024 Oct; 77():101973. PubMed ID: 39025272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of phytochemical compounds of
    Zhang M; Zhang X; Pei J; Guo B; Zhang G; Li M; Huang L
    Heliyon; 2023 Mar; 9(3):e14029. PubMed ID: 36911881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
    Gates LE; Hamed AA
    J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
    Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
    PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
    Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H
    BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?
    Vela JM
    Front Pharmacol; 2020; 11():582310. PubMed ID: 33364957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Network analytics for drug repurposing in COVID-19.
    Siminea N; Popescu V; Sanchez Martin JA; Florea D; Gavril G; Gheorghe AM; Iţcuş C; Kanhaiya K; Pacioglu O; Popa LL; Trandafir R; Tusa MI; Sidoroff M; Păun M; Czeizler E; Păun A; Petre I
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34864885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.
    Xu J; Abdulsalam Khaleel R; Zaidan HK; Faisal Mutee A; Fahmi Fawy K; Gehlot A; Abbas AH; Arias Gonzáles JL; Amin AH; Ruiz-Balvin MC; Imannezhad S; Bahrami A; Akhavan-Sigari R
    Cell Cycle; 2024 Feb; 23(4):405-434. PubMed ID: 38640424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism.
    Yao Y; Zhang Y; Li Z; Chen Z; Wang X; Li Z; Yu L; Cheng X; Li W; Jiang WJ; Wu HJ; Feng Z; Sun J; Fei T
    Biochem Biophys Res Commun; 2023 Oct; 675():113-121. PubMed ID: 37467664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs.
    Eskandarzade N; Ghorbani A; Samarfard S; Diaz J; Guzzi PH; Fariborzi N; Tahmasebi A; Izadpanah K
    Comput Biol Med; 2022 Jul; 146():105575. PubMed ID: 35533462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.
    Rodrigues L; Bento Cunha R; Vassilevskaia T; Viveiros M; Cunha C
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets.
    Zhang J; Li Q; Cruz Cosme RS; Gerzanich V; Tang Q; Simard JM; Zhao RY
    mBio; 2021 Feb; 13(1):e0016922. PubMed ID: 35164548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.
    Uhomoibhi JO; Shode FO; Idowu KA; Sabiu S
    J Mol Graph Model; 2022 Jul; 114():108185. PubMed ID: 35430474
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.